- LexaGene is pleased to announce a three-city tradeshow itinerary for its MiQLab System
- From September 7-9, LexaGene will exhibit and host a podium speaking opportunity at the WVC 93 Conference
- Dr. Regan will also speak at Nashville’s International Veterinary Emergency and Critical Care Conference
- LexaGene will showcase its MiQLab at the San Antonio for the Southwest Veterinary Symposium being held September 23-26
- LexaGene develops fully automated, rapid molecular testing for accurate pathogen detection in human and veterinary diagnostics
- Lexagene Holdings Inc. (LXG) opened trading at C$0.475 per share
LexaGene is pleased to announce a three-city tradeshow itinerary for its MiQLab System.
Beginning this September 7th, the MiQLab will be featured at landmark veterinary events in Las Vegas, Nashville, and San Antonio.
Dr. Jack Regan, LexaGene’s Founder and CEO stated,
“We’re gearing up for a busy and productive fall as we prepare for three of the bigger events in the veterinary marketplace, after a year where all in-person events were cancelled or held virtually. We expect MiQLab’s in-person presence will have significant impact in the veterinary marketplace and look forward to demonstrating how vet practices will greatly benefit from in-clinic PCR diagnostics. Our attendance allows us to take a full-on approach with building brand awareness, exciting potential buyers, and improving our market reach through our revamped marketing and sales strategies.”
From September 7-9, LexaGene will exhibit and host a podium speaking opportunity at this year’s WVC 93 Conference, a gathering of veterinary marketplace leaders featuring over 800 continuing education sessions and 400+ exhibitors.
Dr. Regan will also speak on the topic of “In-Clinic PCR Testing for Pathogen ID and Antibiotic Resistance Detection.” at Nashville’s International Veterinary Emergency and Critical Care Conference.
LexaGene’s senior scientist, Dr. Eric DiBasio, MSc, PhD, will present a poster describing a study using LexaGene’s MiQLab Bacterial and AMR Test for rapid detection of UTI pathogens.
Rounding out the month, LexaGene will travel to San Antonio for the
Southwest Veterinary Symposium being held September 23-26. LexaGene will showcase its MiQLab to one of the largest regional veterinary audiences and will have a podium opportunity. Dr. Manoj Nair, MVSc, PhD, LexaGene’s Director of Applications and Assay Development, will speak on the topic of bringing automated PCR testing for pathogens inside the veterinary hospital. LexaGene develops fully automated, rapid molecular testing for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.
Lexagene Holdings Inc. (LXG) opened trading at C$0.475 per share.
